$IMVT

Immunovant, Inc.

Runway:27 mo

NasdaqMarket cap: —CIK 0001764013

Upcoming catalysts

0 surfaced

No catalysts surfaced for IMVT yet.

Batoclimab 680 mg SC weekly

Generalized Myasthenia Gravis

Batoclimab

Thyroid Eye Disease

Imeroprubart

Chronic Inflammatory Demyelinating Polyneuropathy

RVT-1401 (Administered via subcutaneous injection)

Graves' Ophthalmopathy (GO)

Batoclimab 680 milligrams (mg) subcutaneous (SC) weekly

Chronic Inflammatory Demyelinating Polyneuropathy

IMVT-1401 (batoclimab)

Graves Disease

IMVT-1402

Generalized Myasthenia Gravis

RVT-1401 680 mg/weekly

Warm Autoimmune Hemolytic Anemia

RVT-1401

Graves' Ophthalmopathy

NCT	Drug	Phase	Status	Primary completion
NCT07286006	IMVT-1402	Phase 2	Enrolling By Invitation	2030-03-01
NCT07188844	Batoclimab	Phase 2	Enrolling By Invitation	2028-11-01
NCT07032662	Imeroprubart	Phase 2	Recruiting	2028-08-01
NCT06979531	IMVT-1402	Phase 2	Recruiting	2028-07-01
NCT06727604	IMVT-1402	Phase 2	Recruiting	2028-06-01
NCT07039916	IMVT-1402	Phase 3	Recruiting	2027-12-01
NCT06754462	IMVT-1402	Phase 2	Active Not Recruiting	2027-09-01
NCT07018323	IMVT-1402	Phase 2	Recruiting	2027-05-01
NCT06980805	IMVT-1402	Phase 2	Active Not Recruiting	2026-10-01
NCT05517447	Batoclimab	Phase 3	Terminated	2026-04-02
NCT05524571	Batoclimab	Phase 3	Completed	2026-02-03
NCT05581199	Batoclimab 680 milligrams (mg) subcutaneous (SC) weekly	Phase 2	Active Not Recruiting	2026-01-01
NCT05517421	Batoclimab	Phase 3	Completed	2025-11-02
NCT05907668	IMVT-1401 (batoclimab)	Phase 2	Completed	2025-07-25
NCT05403541	Batoclimab 680 mg SC weekly	Phase 3	Active Not Recruiting	2025-01-10
NCT04253236	RVT-1401 680 mg/weekly	Phase 2	Terminated	2021-04-01
NCT03938545	RVT-1401	Phase 2	Terminated	2021-02-02
NCT03863080	RVT-1401	Phase 2	Completed	2020-10-07
NCT03922321	RVT-1401	Phase 2	Completed	2020-02-29